Cargando…

Combined antihypertensive and statin therapy for the prevention of cardiovascular events in patients with hypertension without complications: protocol for a systematic review and meta-analysis

INTRODUCTION: High blood pressure (BP) affects over 40% of adults over the age of 25 worldwide and is the leading global risk factor for death or disability. Hypertension is also the most important risk factor for endovascular atherosclerosis, which, when combined with other cardiovascular risk fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ying, Kuang, Ze-Min, Feng, Shu-Jun, Jiang, Long, Chen, Qiu-Xian, Ji, Xiao-Yun, Cheng, Wen-Li, Hu, Hong-Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988117/ https://www.ncbi.nlm.nih.gov/pubmed/29858408 http://dx.doi.org/10.1136/bmjopen-2017-019719

Ejemplares similares

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Genetically predicted hypertension, antihypertensive drugs, and risk of erectile dysfunction: a Mendelian randomization study
por: Zhao, Cong, et al.
Publicado: (2023)

Factors affecting the changes in antihypertensive medications in patients with hypertension
por: Chung, Tae Kyu, et al.
Publicado: (2022)

Long-term comparative effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events: a population-based retrospective inception cohort study in the Netherlands
por: Li, Xuechun, et al.
Publicado: (2023)

Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)
por: Zoungas, Sophia, et al.
Publicado: (2023)

Sex differences in the efficacy of antihypertensive treatment in preventing cardiovascular outcomes and reducing blood pressure: protocol for a systematic review and meta-analysis
por: Gasbarrino, Karina, et al.
Publicado: (2020)

Comparative efficacy and acceptability of different antihypertensive drug classes for cardiovascular disease prevention: protocol for a systematic review and network meta-analysis
por: Jussil, Heidi, et al.
Publicado: (2021)

Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
por: Byrne, Paula, et al.
Publicado: (2019)

U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy
por: Zeng, Rui-Xiang, et al.
Publicado: (2022)

Prognostic implication of left ventricular hypertrophy regression after antihypertensive therapy in patients with hypertension
por: Kim, Hyue Mee, et al.
Publicado: (2022)

Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials
por: Wang, Xinyi, et al.
Publicado: (2022)

Statin adherence and risk of acute cardiovascular events among women: a cohort study accounting for time-dependent confounding affected by previous adherence
por: Lavikainen, Piia, et al.
Publicado: (2016)

Targets of statins intervention in LDL-C metabolism: Gut microbiota
por: Sun, ChangXin, et al.
Publicado: (2022)

Effect of adherence to antihypertensive medication on stroke incidence in patients with hypertension: a population-based retrospective cohort study
por: Lee, Hyo Jung, et al.
Publicado: (2017)

The Association of Stage 1 Hypertension, Defined by the 2017 ACC/AHA Guidelines, With Cardiovascular Events Among Rural Women in Liaoning Province, China
por: Wu, Jiake, et al.
Publicado: (2021)

Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial
por: Garrison, Scott R, et al.
Publicado: (2022)

Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials
por: Zhou, Zhen, et al.
Publicado: (2017)

Editorial: Women in cardiovascular therapeutics
por: Yin, Liya, et al.
Publicado: (2023)

Use of Antihypertensive Drugs During Preeclampsia
por: Odigboegwu, Obinnaya, et al.
Publicado: (2018)

Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease
por: Byrne, Paula, et al.
Publicado: (2018)

Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
por: Shah, Aditya, et al.
Publicado: (2022)

Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis
por: Nayak, Agnish, et al.
Publicado: (2018)

Antihypertensive medication use during pregnancy in a real-world cohort of patients diagnosed with a hypertensive disorder of pregnancy
por: Garcia, Julian E., et al.
Publicado: (2023)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

Association between statin use and the prognosis of patients with acute myocardial infarction complicated with diabetes
por: Lu, Xuehao, et al.
Publicado: (2022)

Isolated Diastolic Hypertension and Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis of Cohort Studies With 489,814 Participants
por: Huang, Mingyan, et al.
Publicado: (2022)

Tackling statin intolerance with n-of-1 trials (TaSINI) in primary care: protocol for a feasibility randomised trial to increase statin adherence
por: Tudor, Kate, et al.
Publicado: (2020)

Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study
por: Yang, Quanhe, et al.
Publicado: (2017)

Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models
por: Akyea, Ralph K, et al.
Publicado: (2020)

Cardiovascular Hypertension-Mediated Organ Damage in Hypertensive Urgencies and Hypertensive Outpatients
por: Vallelonga, Fabrizio, et al.
Publicado: (2022)

Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review
por: Mansilla-Rodríguez, María Elena, et al.
Publicado: (2023)

Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England
por: O'Keeffe, Aidan G, et al.
Publicado: (2015)

Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials
por: Boczar, Kevin Emery, et al.
Publicado: (2022)

Hydrophilic or Lipophilic Statins?
por: Climent, Elisenda, et al.
Publicado: (2021)

Cerebrovascular Disease and Statins
por: Beltrán Romero, Luis M., et al.
Publicado: (2021)

Racial and Sex Differences in the Response to First-Line Antihypertensive Therapy
por: Clemmer, John S., et al.
Publicado: (2020)

Narrative update of clinical trials with antihypertensive drugs in children and adolescents
por: Redon, Josep, et al.
Publicado: (2022)

Dynamic changing smoking habits and cardiovascular events in patients newly diagnosed with hypertension, diabetes, or dyslipidemia: a national cohort study
por: Song, Shinjeong, et al.
Publicado: (2023)

Editorial: Hypertensive disorders of pregnancy and the cardiovascular system: Causes, consequences, prevention and treatment
por: Dierickx, Inge, et al.
Publicado: (2023)

Cardiovascular Complications of COVID-19 Vaccines
por: Liu, Runyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r91n1g63d2hg0lb3lfb6b0apui